Captor Therapeutics Revenue and Competitors

Wrocław, Poland

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Captor Therapeutics's estimated annual revenue is currently $8.3M per year.(i)
  • Captor Therapeutics's estimated revenue per employee is $77,500

Employee Data

  • Captor Therapeutics has 107 Employees.(i)
  • Captor Therapeutics grew their employee count by 1% last year.

Captor Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.7M177-12%N/AN/A
#2
$12.1M15621%N/AN/A
#3
$10.7M1388%N/AN/A
#4
$0.3M4-20%N/AN/A
#5
$100.7M129910%N/AN/A
#6
$8.3M1071%N/AN/A
#7
$8.5M1108%N/AN/A
#8
$104.3M8413%N/AN/A
#9
$5.6M7233%N/AN/A
#10
$8.7M11238%N/AN/A
Add Company

What Is Captor Therapeutics?

Captor Therapeutics is a high-tech pharmaceutical company focused on targeting the undruggable proteome. Our mission is to transform lives of patients suffering from cancer, viral infections, and inflammatory and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to ease patients'​ burden and cure conditions that so far have only been poorly treatable.​ Our company is a pioneer of a small molecule-induced targeted degradation of proteins with particular expertise covering degradation of membrane proteins. We are privately held start-up with total of 65+ years of experience in pharmaceutical industry. We collaborate closely with renowned biology and chemistry experts from top American and European academic institutions.

keywords:N/A

N/A

Total Funding

107

Number of Employees

$8.3M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Captor Therapeutics News

2022-04-13 - Global Roundup: A CAR-T Partnership and CDR-Life Nabs $76M to ...

Australia's Chimeric Therapeutics has partnered with WuXi ATU, a global ... Captor Therapeutics: Based in Poland, Captor announced the...

2022-04-06 - Captor Therapeutics Invited to TPD Panel at the 8th Annual LSX ...

Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop...

2022-04-06 - Captor Therapeutics Announcements | Captor Therapeutics: Captor ...

Dr. Tom Shepherd, Chief Executive Officer of Captor Therapeutics, will participate in an expert panel discussion focused on Targeted Protein...

2020-12-22 - Sosei Heptares : and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

TOKYO and CAMBRIDGE, England, Dec. 22, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565), a world leader in GPCR-focused structure-based drug design and development, and Captor Therapeutics SA ("Captor"; Wroclaw, Poland and Allschwil, Switzerland), a European leader in tar ...

2020-12-22 - SOSEI GROUP CORPORATION Sosei Heptares : and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

TOKYO and CAMBRIDGE, England, Dec. 22, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565), a world leader in GPCR-focused structure-based drug design and development, and Captor Therapeutics SA ("Captor"; Wroclaw, Poland and Allschwil, Switzerland), a European leader in tar ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.6M11925%N/A
#2
$8.9M123-34%N/A
#3
$11.2M1405%N/A
#4
$17.2M20840%N/A
#5
$17.1M2221%N/A